eyp-1901
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jan 20, 2021 (NCT04747197)
Timeline
Indications
Mechanism of action
FLT4 inhibitor
KDR inhibitor
FLT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06683742 | Phase 3 | Dec 31, 2024 | Eyepoint Pharmaceuticals |
| NCT06668064 | Phase 3 | Oct 22, 2024 | Eyepoint Pharmaceuticals |
| NCT06099184 | Phase 2 | Jan 15, 2024 | Eyepoint Pharmaceuticals |
| NCT05383209 | Phase 2 | Aug 31, 2022 | Eyepoint Pharmaceuticals |
| NCT05381948 | Phase 2 | Jul 28, 2022 | Eyepoint Pharmaceuticals |
| NCT04747197 | Phase 1 | Jan 20, 2021 | Eyepoint Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eyepoint Pharmaceuticals | For profit | 6 | 6 | 3 | 2021 |
1 organizations
Page 1 / 1